Department of Paediatrics - Foundations IRCCS Policlinico San Matteo, University of Pavia, Italy.
Ital J Pediatr. 2009 Oct 23;35(1):31. doi: 10.1186/1824-7288-35-31.
Allergen specific immunotherapy (SIT) is the practice of administering gradually increasing doses of the specific causative allergen to reduce the clinical reactivity of allergic subjects, and is the only treatment targeting the causes of hypersensitivity and not only the symptoms, as done by drugs. The traditional, subcutaneous immunotherapy (SCIT) was burdened by the problem of systemic reactions which may be sometimes severe and - though very rarely - even fatal. This was the background to develop non injections routes for SIT and particularly sublingual immunotherapy (SLIT), that emerged as a real treatment option for respiratory allergy.A number of studies was conducted to evaluate efficacy and safety of SLIT, the first meta-analysis - including 22 placebo-controlled trials - concluded for positive results in both issues, but the number of studies on children was too low to draw definite conclusions. Since then, many other studies became available and make possible to analyze SLIT in children in its well defined aspects as well as in sides still requiring more solid data.
变应原特异性免疫治疗(SIT)是指逐渐给予特定变应原剂量以减少过敏患者临床反应性的做法,是唯一针对过敏反应病因而不仅是症状的治疗方法,如药物治疗。传统的皮下免疫治疗(SCIT)存在全身性反应的问题,有时可能很严重,尽管非常罕见,但甚至可能致命。这就是开发 SIT 的非注射途径,特别是舌下免疫治疗(SLIT)的背景,它已成为呼吸道过敏的一种真正的治疗选择。已经进行了多项研究来评估 SLIT 的疗效和安全性,第一项荟萃分析——包括 22 项安慰剂对照试验——得出了在这两个方面都有积极结果的结论,但关于儿童的研究数量太少,无法得出明确的结论。从那时起,出现了许多其他研究,使我们能够分析儿童 SLIT 的各个方面,以及仍需要更可靠数据的方面。